Figure 9.
Performance of prognosis signature in predicting patients survival and immunotherapy. (A) The performance of our signature in predicting patients survival in the training cohort; (B) The performance of our signature in predicting patients survival in the internal validation cohort; (C) The performance of our signature in predicting patients survival in external validation cohort; (D) Correlation of risk score and TIDE; (E) The risk score level in immunotherapy responders and non-responders; (F) Percentage of immunotherapy responder in patients with high and low MYBL1 expression. ***P <0.001.